in Latent Tuberculosis Infection


CEYLAN A. N., CANAT H. D., Komec S., Gulmez A.

Clinical Laboratory, cilt.71, sa.3, ss.525-530, 2025 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 71 Sayı: 3
  • Basım Tarihi: 2025
  • Doi Numarası: 10.7754/clin.lab.2024.241003
  • Dergi Adı: Clinical Laboratory
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.525-530
  • Anahtar Kelimeler: latent tuberculosis infection, interferon-gamma release assay, fluorescent immunoassay, TB-Feron FIA
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: Tuberculosis is still a significant global health challenge, with latent tuberculosis infection (LTBI) posing a risk for the development of active disease. This study aimed to compare the performance of the STANDARD F TB-Feron FIA test with the QuantiFERON-TB Gold Plus, a test endorsed by the World Health Organization (WHO), in detecting LTBI. Methods: We included 137 participants, out of which 58.4% were healthy and 41.6% were undergoing immunosuppressive treatment. Results: The agreement between QFT-Plus and TB-Feron FIA was substantial, with an overall concordance of 83.0% and a Cohen's kappa coefficient of 0.631 (p < 0.001). The TB-Feron FIA test demonstrated a sensitivity of 84.38% and a specificity of 87.10% compared to QFT-Plus. When TB-Feron FIA cutoff values were recalculated according to QFT Plus results, the value of 0.37 gave the highest sensitivity and specificity (84.37% and 88.42%). Conclusions: Our findings suggest that TB-Feron FIA is a reliable alternative for diagnosing LTBI, with performance comparable to QFT-Plus, especially in immunosuppressive patients where sensitivity was 100%. Further studies are warranted to confirm these results in broader populations.